Bardia A et al. EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting. SABCS 2022;Abstract GS3-01.
Cescon DW et al. Can a late interception by circulating tumor DNA deliver a win in estrogen receptor-positive early breast cancer? J Clin Oncol 2022;40(22):2395-7. Abstract
Cheung Y-MM et al. Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer. Breast Cancer Res Treat 2022;192(2):303-11. Abstract
Connolly RM, Miller KD. Back to the beginning: The role of ovarian suppression in management of hormone sensitive breast cancer in premenopausal women. J Clin Oncol 2023;41(7):1339-41. Abstract
Francis PA et al. Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT. J Clin Oncol 2023;41(7):1370-5. Abstract
Giordano J et al. Is there a role of the oncotype DX breast recurrence score genomic assay in estrogen receptor-low positive breast cancer? ASCO 2022;Abstract 564.
Lambertini M et al. Gonadotropin-releasing hormone agonist during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systemic review and meta-analysis of individual patient-level data. J Clin Oncol 2018;36(19):1981-90. Abstract
Leone JP et al. Survival in male breast cancer over the past 3 decades. J Nat Cancer Inst 2023;[Online ahead of print]. Abstract
Leone JP et al. Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer. Cancer 2022;128(21):3796-803. Abstract
Leone JP et al. Estimating long-term mortality in women with hormone receptor-positive breast cancer: The ‘ESTIMATE’ tool. Eur J Cancer 2022;173:20-9. Abstract
Leone JP et al. Mortality risks over 20 years in men with stage I-III hormone receptor-positive breast cancer. SABCS 2022;Abstract PD6-08.
Lipsyc-Sharf M et al. Circulating tumor DNA and late recurrence in high-risk hormone receptor-positive, human epidermal growth factor 2-negative breast cancer. J Clin Oncol 2022;40(22):2408-19. Abstract
Love N et al. HER2 and estrogen receptor status drive decisions regarding the use of neoadjuvant chemotherapy. SABCS 2015;Abstract P1-14-20.
Mittendorf EA et al. Impact of RxPONDER and monarchE on the surgical management of axilla in patients with breast cancer. J Clin Oncol 2022;40(29):3361-4. Abstract
Modi S et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 2022;387(1):9-20. Abstract
Modi S et al. Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. ASCO 2022;Abstract LBA3.
Moore HCF et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015:372(10):923-32. Abstract
Morganti S et al. Clinicopathological characteristics, treatment patterns and disease outcomes of germline BRCA1/2 carriers with early stage HER2-negative breast cancer and potential eligibility for adjuvant olaparib. SABCS 2022;Abstract P2-01-02.
Morganti S, Tolaney SM. Role of immunotherapy in early- and late-stage triple-negative breast cancer. Hematol Oncol Clin North Am 2023;37(1):133-50. Abstract
Oktay K et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2018:36(19):1994-2001. Abstract
Oliveira M et al. Camizestrant, a next-generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial. SABCS 2022;Abstract GS3-02.
Pagani O et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: Long-term follow-up of the combined TEXT and SOFT trials. J Clin Oncol 41(7):1376-82. Abstract
Prat A et al. An overview of clinical development of agents for metastatic or advanced breast cancer without ERBB2 amplification (HER2-low). JAMA Oncol 2022;[Online ahead of print]. Abstract
Schlam I et al. How I treat HER2-low advanced breast cancer. Breast 2023;67:116-23. Abstract
Schlam I et al. The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced pretreated HER2-low breast cancer. Expert Rev Anticancer Ther 2023;[Online ahead of print]. Abstract
Sparano JA et al. Trial assigning individualized options for treatment (TAILORx): An update including 12-year event rates. SABCS 2022;Abstract GS1-05.
Tarantino P et al. Comprehensive genomic characterization of HER2-low breast cancer. SABCS 2022;Abstract HER2-05.
Tarantino P et al. Immunotherapy for early triple negative breast cancer: Research agenda for the next decade. Breast Cancer 2022;8(1):23. Abstract
Tarantino P et al. Prognostic and biological significance of ERBB2-low expression in early-stage breast cancer. JAMA Oncol 2022;8(8):1177-83. Abstract
Tolaney SM, Shaw L. Immunotherapy for the treatment of triple-negative breast cancer. J Adv Pract Oncol 2022;13(3):298-301. Abstract
Tutt ANJ et al. Pre-specified event driven analysis of overall survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer. ESMO Virtual Plenary 2022;Abstract VP1.
Tung NM et al. Adjuvant PARP inhibitors in patients with high-risk early-stage HER2-negative breast cancer and germline BRCA mutations: ASCO hereditary breast cancer guideline rapid recommendation update. J Clin Oncol 2021;39(26):2959-61. Abstract
Turner NC et al. Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the phase III CAPItello-291 trial. SABCS 2022;Abstract GS3-04.